Reduced dose of PTCy followed by adjuvant α-galactosylceramide enhances GVL effect without sacrificing GVHD suppression

Posttransplantation cyclophosphamide (PTCy) has become a popular option for haploidentical hematopoietic stem cell transplantation (HSCT). However, personalized methods to adjust immune intensity after PTCy for each patient’s condition have not been well studied. Here, we investigated the effects of...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Makoto, Meguri, Yusuke, Ikegawa, Shuntaro, Kondo, Takumi, Sumii, Yuichi, Fukumi, Takuya, Iwamoto, Miki, Sando, Yasuhisa, Sugiura, Hiroyuki, Asada, Noboru, Ennishi, Daisuke, Tomida, Shuta, Fukuda-Kawaguchi, Emi, Ishii, Yasuyuki, Maeda, Yoshinobu, Matsuoka, Ken-ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222309/
https://www.ncbi.nlm.nih.gov/pubmed/34162921
http://dx.doi.org/10.1038/s41598-021-92526-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8222309/
https://www.ncbi.nlm.nih.gov/pubmed/34162921
http://dx.doi.org/10.1038/s41598-021-92526-z

Ejemplares similares